Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid

Neurobiology of Aging

Volumn 23, Issue 4, 2002, Pages 485-508

  Teunissen, C E ^a   De Vente, J ^a   Steinbusch, H W M ^a   De Bruijn, C ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Biochemical markers; Cholesterol; CSF; Diagnosis of dementia; Inflammation; Oxidative stress; Plaque proteins; Plasma; Serum; Vitamins

Indexed keywords

3 NITROTYROSINE; 8 HYDROXYDEOXYGUANOSINE; ALPHA 1 ANTICHYMOTRYPSIN; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ANTIBODY; ASCORBIC ACID; BIOCHEMICAL MARKER; CHOLESTEROL; CYANOCOBALAMIN; FOLIC ACID; GLIAL FIBRILLARY ACIDIC PROTEIN; GLOBIN; GLYCOPROTEIN GP 130; HOMOCYSTEINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; ISOPROSTANE; PYRIDOXINE; RETINOL; TAU PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ALZHEIMER DISEASE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CHOLESTEROL BLOOD LEVEL; CLINICAL EXAMINATION; HOMEOSTASIS; HUMAN; INFLAMMATION; NERVE DEGENERATION; NEUROPSYCHOLOGICAL TEST; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; SENILE PLAQUE;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CHOLESTEROL; HUMANS; INFLAMMATION; OXIDATIVE STRESS; VITAMINS;

EID: 0036250622     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(01)00328-1     Document Type: Review

References (315)

1. Haptoglobin
2. No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease
3. Anti-inflammatory therapy for Alzheimer's disease: Implications of the prednisone trial
4. Amyloid beta-peptide stimulates nitric oxide production in astrocytes through an NFkappaB-dependent mechanism
5. Quantification of glial fibrillary acidic protein (GFAP) in human body fluids by means of ELISA employing a monoclonal antibody
6. Relevance of vitamins, homocysteine and other metabolites in neuropsychiatric disorders
7. Cerebrospinal fluid levels of alpha-secretase-cleaved soluble amyloid precursor protein mirror cognition in a Swedish family with Alzheimer disease and a gene mutation
8. Blood levels of histamine, IL-1 beta, and TNF-alpha in patients with mild to moderate Alzheimer disease
9. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: Differences between early- and late-onset Alzheimer disease and stability during the course of disease
10. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample
11. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice
12. Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment
13. Serum IL-6, and IL-6 soluble receptor in Alzheimer's disease
14. Nitration of manganese superoxide dismutase in cerebrospinal fluids is a marker for peroxynitrite-mediated oxidative stress in neurodegenerative diseases
15. Cerebrospinal fluid tau protein as a potential diagnostic marker in Alzheimer's disease
16. CSF phosphorylated tau protein, and mild cognitive impairment: A prospective study
17. No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia
18. Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease
19. Determination of S-100 and glial fibrillary acidic protein concentrations in cerebrospinal fluid after brain infarction
20. Isoprostanes-prostaglandin-like compounds formed in vivo independently of cyclooxygenase: Use as clinical indicators of oxidant damage
21. Methylation reactions in the formation and metabolism of catecholamines and other biogenic amines
22. Aging, energy, and oxidative stress in neurodegenerative diseases
23. ALS, SOD, and peroxynitrite
24. Activation of the contact system in cerebrospinal fluid of patients with Alzheimer disease
25. Systemic oxidative stress and cognitive performance in the population-based EVA study
26. Beta-amyloid peptide secretion by a microglial cell line is induced by beta-amyloid-(25-35) and lipopolysaccharide
27. Removal of cholesterol from extrahepatic sources by oxidative mechanisms
28. Importance of a novel oxidative mechanism for elimination of brain cholesterol
29. Cholesterol homeostasis in human brain: Turnover of 24S- hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation
30. Combination of the different biological markers for increasing specificity of in vivo Alzheimer's testing
31. Intrathecal synthesis of immunoglobulins in patients with Alzheimer's disease
32. Cerebrospinal fluid tau levels increase with age in healthy individuals
33. Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele epsilon 4 during 14 months follow-up
34. IL-1 beta, and IL-6 are elevated in the cerebrospinal fluid of Alzheimer's, and de novo Parkinson's disease patients
35. Proteins in serum and cerebrospinal fluid in demented patients
36. Serotonin-immune interactions in elderly volunteers and in patients with Alzheimer's disease (DAT): Lower plasma tryptophan availability to the brain in the elderly and increased serum IL-6 in DAT
37. Relationships between cholesterol, apolipoprotein E polymorphism and dementia: A cross-sectional analysis from the PAQUID study
38. Haptoglobin
39. Neuropathological stageing of Alzheimer-related changes
40. Endogenous nitric oxide synthesis: Biological functions and pathophysiology
41. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs
42. Plasma levels of 24S-hydroxycholesterol reflect the balance between cerebral production and hepatic metabolism and are inversely related to body surface
43. Elevated free nitrotyrosine levels, but not protein-bound nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)-like disease implicate tyrosine nitration as an aberrant in vivo property of one familial ALS-linked superoxide dismutase 1 mutant
44. A high plasma concentration of TNF-alpha is associated with dementia in centenarians
45. [Tau protein. A potential biological indicator for early detection of Alzheimer disease (see comments)]
46. Plasma total homocysteine and cognitive performance in a volunteer elderly population
47. Alzheimer's risk associated with human apolipoprotein E, alpha-2 macroglobulin, and lipoprotein receptor related protein polymorphisms: Absence of genetic interactions, and modulation by gender
48. Serum TNF in Alzheimer's disease, and multi-infarct dementia
49. Cerebrospinal fluid IL-1 beta (IL-1 beta) in Alzheimer's disease and neurological disorders
50. Structural correlates of cognitive deficits in a selected group of patients with Alzheimer's disease
51. Serum cytokine levels in patients with Alzheimer's disease
52. Neuroprotective properties of nitric oxide
53. Hyperhomocysteinemia: An independent risk factor for vascular disease
54. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease
55. Increased GFAp levels in CSF as a marker of organicity in patients with Alzheimer's disease, and other types of irreversible chronic organic brain syndrome
56. Peroxynitrite formation within the central nervous system in active multiple sclerosis
57. Evidence for the production of peroxynitrite in inflammatory CNS demyelination
58. Perivascular astrocytes within Alzheimer's disease plaques
59. Expression of the Alzheimer amyloid-promoting factor antichymotrypsin is induced in human astrocytes by IL-1
60. Alzheimer neuropathologic alterations in aged cognitively normal subjects
61. Nitric oxide in neurodegeneration
62. Role of APOE in dementia: A critical reappraisal
63. Cerebral hypoperfusion, capillary degeneration, and development of Alzheimer disease
64. Haptoglobin polymorphism, iron metabolism and mortality in HIV infection
65. Ratio of S-nitrosohomocyst(e)ine to homocyst(e)ine or other thiols determines neurotoxicity in rat cerebrocortical cultures
66. Mitochondria in exercise-induced oxidative stress
67. Human kallikrein 6 as a biomarker of alzheimer's disease
68. Anti-NGF autoantibodies, and NGF in sera of Alzheimer patients, and in normal subjects in relation to age
69. Neuropathological changes in scrapie and Alzheimer's disease are associated with increased expression of apolipoprotein E and cathepsin D in astrocytes
70. Cholesterol metabolism in the brain
71. Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism
72. IL-1 stimulates the beta-amyloid precursor protein promoter
73. Lithostathine and pancreatitis-associated protein are involved in the very early stages of Alzheimer's disease
74. Folate status, vascular disease and cognition in elderly Canadians
75. Molecular profile of reactive astrocytes - Implications for their role in neurologic disease
76. Neuroinflammation and Alzheimer disease: Clinical and therapeutic implications
77. The importance of inflammatory mechanisms for the development of Alzheimer's disease
78. C3, and haptoglobin polymorphism in dementia of the Alzheimer type
79. Serum and cerebrospinal fluid proteins and the blood-brain barrier in Alzheimer's disease and multi-infarct dementia
80. Unchanged levels of interleukins, neopterin, interferon-gamma and TNF-alpha in cerebrospinal fluid of patients with dementia of the Alzheimer type
81. The constitution of cerebrosterol, a hydroxysteroid isolated from horse brain
82. IL-6: A cytokine for gerontologists
83. Elevated circulating TNF levels in Alzheimer's disease
84. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician
85. Plasma chain-breaking antioxidants in Alzheimer's disease, vascular dementia and Parkinson's disease
86. Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group
87. Haptoglobin groups in dementia of Alzheimer type and multi-infarct dementia
88. Inhibition of L-glutamate uptake into synaptic vesicles
89. Inflammatory pathogenesis in Alzheimer's disease: Biological mechanisms and cognitive sequeli
90. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype
91. NGF attenuates 3-nitrotyrosine formation in a 3-NP model of Huntington's disease
92. Soluble IL-1 receptor type II levels are elevated in cerebrospinal fluid in Alzheimer's disease patients
93. Acute-phase proteins in Alzheimer's disease
94. Alzheimer's disease: Initial report of the purification, and characterization of a novel cerebrovascular amyloid protein
95. Microglia as mediators of inflammatory and degenerative diseases
96. Association between nutritional status and cognitive functioning in a healthy elderly population
97. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease
98. IL-1 expression in different plaque types in Alzheimer's disease: Significance in plaque evolution
99. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments
100. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology
101. Vitamin E, and Alzheimer disease: The basis for additional clinical trials
102. Thermolabile methylenetetrahydrofolate reductase gene and the risk of cognitive impairment in those over 85
103. Antioxidant defence mechanisms: From the beginning to the end (of the beginning)
104. Reactive oxygen species and the central nervous system
105. Role of free radicals and catalytic metal ions in human disease: An overview
106. IL-6 is not altered in cerebrospinal fluid of first-degree relatives, and patients with Alzheimer's disease
107. Decreased soluble IL-6 receptor in cerebrospinal fluid of patients with Alzheimer's disease
108. Discriminant power of combined cerebrospinal fluid tau protein and of the soluble IL-6 receptor complex in the diagnosis of Alzheimer's disease
109. Alpha 1-antichymotrypsin level in cerebrospinal fluid is closely associated with late onset Alzheimer's disease
110. Increased soluble TNF receptor levels in the serum of elderly people
111. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation
112. Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation
113. Release of glial tissue-specific proteins after acute stroke: A comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein
114. Phospholipid methylation and biological signal transmission
115. Cerebrospinal fluid levels of amyloid precursor protein and amyloid beta-peptide in Alzheimer's disease and major depression - Inverse correlation with dementia severity
116. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF
117. Age-related changes in antioxidant enzymes, superoxide dismutase, catalase, glutathione peroxidase and glutathione in different regions of mouse brains
118. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay
119. Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase
120. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease
121. Visualization of A beta 42(43) and A beta 40 in senile plaques with end- specific A beta monoclonals: Evidence that an initially deposited species is A beta 42(43)
122. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD
123. Vitamin E, and Alzheimer's disease in subjects with Down's syndrome
124. Lipid peroxidation and free radical scavengers in Alzheimer's disease
125. Neuropathology of Alzheimer's disease: A critical update
126. Increased cerebrospinal fluid tau in patients with Alzheimer's disease
127. Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression
128. Cerebrospinal fluid levels of alpha-tocopherol (vitamin E) in Alzheimer's disease
129. Cerebrospinal fluid protein variations in common to Alzheimer's disease and schizophrenia
130. Is metabolic evidence for vitamin B-12 and folate deficiency more frequent in elderly patients with Alzheimer's disease?
131. Cholesterol for synthesis of myelin is made locally, not imported into brain
132. Serum IL-6 levels correlate with the severity of dementia in Down syndrome, and in Alzheimer's disease
133. Total homocysteine and cognitive decline in a community-based sample of elderly subjects: The Rotterdam Study
134. An activity in rat tissues that modifies nitrotyrosine-containing proteins
135. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: A study in Japan
136. Apolipoprotein E4 accelerates dementia, and increases cerebrospinal fluid tau levels in Alzheimer's disease
137. S-nitrosation ameliorates homocysteine-induced neurotoxicity, and calcium responses in primary culture of rat cortical neurons
138. IL-6 family of cytokines, and gp130
139. Incorrect diagnosis of Alzheimer's disease. A clinicopathologic study
140. The neurotoxic effect of 24-hydroxycholesterol on SH-SY5Y human neuroblastoma cells
141. Identification of the haemoglobin scavenger receptor
142. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity
143. Seizures induced by homocysteine in rats during ontogenesis
144. Denitration of peroxynitrite-treated proteins by 'protein nitratases' from rat brain and heart
145. High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease
146. Elevated abeta42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AbetaPP metabolism
147. Tau protein in cerebrospinal fluid is significantly increased at the earliest clinical stage of Alzheimer disease
148. Nutritional status and cognitive functioning in a normally aging sample: A 6-y reassessment
149. Biological and clinical significance of haptoglobin polymorphism in humans
150. Effect of haptoglobin on the metabolism of vitamin C
151. Decreased alpha-secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer's disease
152. Mannan-binding lectin in human serum, cerebrospinal fluid and brain tissue and its role in Alzheimer's disease
153. Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: IL-1beta, IL-6, IL-1 receptor antagonist, TNF-alpha, the soluble TNF receptors I and II, and alpha1- antichymotrypsin
154. Apolipoprotein E, and the CNS response to injury
155. Apolipoprotein E epsilon 4 allele in association with global cognitive performance, and CSF markers in Alzheimer's disease
156. The -491AA polymorphism in the APOE gene is associated with increased plasma apoE levels in Alzheimer's disease
157. Identification of cognitive impairment in the elderly: Homocysteine is an early marker
158. Apolipoprotein E (apoE) polymorphism, and its influence on ApoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer's disease
159. Exploring the etiology of Alzheimer disease using molecular genetics
160. Elevated serum total and LDL cholesterol in very old patients with Alzheimer's disease
161. Blood levels of alpha-1-antichymotrypsin and risk factors for Alzheimer's disease: Effects of gender and apolipoprotein E genotype
162. Increased serum alpha 1-antichymotrypsin in patients with probable Alzheimer's disease: An acute phase reactant without the peripheral acute phase response
163. Increased plasma levels of IL-1, IL-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: Peripheral inflammation or signals from the brain?
164. Serum vitamin B12, C and folate concentrations in the New Mexico elder health survey: Correlations with cognitive and affective functions
165. Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer's disease patients are increased at follow up and show a correlation with levels of tau protein
166. Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group
167. Increased DNA oxidation, and decreased levels of repair products in Alzheimer's disease ventricular CSF
168. Ratio of 8-hydroxyguanine in intact DNA to free 8-hydroxyguanine is increased in Alzheimer disease ventricular cerebrospinal fluid
169. CDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain
170. Cholesterol homeostasis in human brain: Evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation
171. Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer, and vascular demented patients
172. A review on the acute phase response in major depression
173. Inflammatory markers in younger vs elderly normal volunteers and in patients with Alzheimer's disease
174. Apolipoprotein E: From atherosclerosis to Alzheimer's disease, and beyond
175. Comparison of the effect of alpha-lipoic acid and alpha-tocopherol supplementation on measures of oxidative stress
176. The role of oxidative stress in Alzheimer disease
177. Increased cerebrospinal fluid fas (Apo-1) levels in Alzheimer's disease. Relationship with IL-6 concentrations
178. Relationship of IL-1 beta and beta 2-microglobulin with neuropeptides in cerebrospinal fluid of patients with dementia of the Alzheimer type
179. IL-6 (IL-6), and soluble forms of IL-6 receptors are not altered in cerebrospinal fluid of Alzheimer's disease patients
180. Activation of gp130 by IL-6/soluble IL-6 receptor induces neuronal differentiation
181. Evidence for changes in the Alzheimer's disease brain cortical membrane structure mediated by cholesterol
182. Serum concentration of alpha 1-antichymotrypsin is elevated in patients with senile dementia of the Alzheimer type
183. Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome
184. Alpha 1-antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia
185. Haptoglobin phenotypes in dementia of the Alzheimer type
186. Increased 3-nitrotyrosine in brains of Apo E-deficient mice
187. Altered blood-brain-barrier function in Alzheimer's disease?
188. Cellular signaling roles of TGF beta, TNF alpha and beta APP in brain injury responses and Alzheimer's disease
189. Activation of NF-kappaB protects hippocampal neurons against oxidative stress-induced apoptosis: Evidence for induction of manganese superoxide dismutase and suppression of peroxynitrite production and protein tyrosine nitration
190. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease
191. Total serum homocysteine in senile dementia of Alzheimer type
192. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains
193. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR
194. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies
195. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
196. Tau protein in cerebrospinal fluid: A new diagnostic and prognostic marker in Alzheimer disease?
197. Antihistone and anti-dsDNA autoantibodies in Alzheimer's disease and vascular dementia
198. Serum autoantibodies against glial fibrillary acidic protein in brain aging and senile dementias
199. Serum anti-GFAP and anti-S100 autoantibodies in brain aging, Alzheimer's disease and vascular dementia
200. Use of antioxidant supplements and its association with cognitive function in a rural elderly cohort: The MoVIES Project. Monongahela Valley Independent Elders Survey
201. Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease
202. Apolipoprotein E allelic influence on human cerebrospinal fluid apolipoproteins
203. Increased CSF F2-isoprostane concentration in probable AD
204. Cerebrospinal fluid F2-isoprostanes are elevated in Huntington's disease
205. Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease
206. The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or with APOE genotype in Alzheimer's disease patients
207. No difference in plasma or urinary F2-isoprostanes among patients with Huntington's disease or Alzheimer's disease and controls
208. Elevated CSF prostaglandin E2 levels in patients with probable AD
209. Cerebrospinal fluid tau protein levels in demented and nondemented alcoholics
210. Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids
211. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism
212. Free radical-induced generation of isoprostanes in vivo. Evidence for the formation of D-ring and E-ring isoprostanes
213. The isoprostanes. Current knowledge and directions for future research
214. Formation of novel isoprostane-like compounds from docosahexaenoic acid
215. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease
216. Genetic and biochemical markers for Alzheimer's disease: Recent developments
217. Apolipoprotein E protects against neuropathology induced by a high-fat diet, and maintains the integrity of the blood-brain barrier during aging
218. Possible link between lipid metabolism and cerebral amyloid angiopathy in Alzheimer's disease: A role for high-density lipoproteins?
219. Tau protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease
220. EUROCARE: A cross-national study of co-resident spouse carers for people with Alzheimer's disease: II - A qualitative analysis of the experience of caregiving
221. GFAP mRNA increases with age in rat, and human brain
222. Immunochemical analysis of some proteins in cerebrospinal fluid and serum of patients with ischemic strokes
223. Hyperhomocysteinaemia - A common finding in a psychogeriatric population
224. The plasma homocysteine concentration is better than that of serum methylmalonic acid as a marker for sociopsychological performance in a psychogeriatric population
225. Basic and clinical studies on ApoE gene typing by line probe assay (LiPA) as a biological marker for Alzheimer's disease and related disorders: Multicenter study in Japan
226. Cerebrospinal fluid levels of amyloid beta-protein in Alzheimer's disease: Inverse correlation with severity of dementia and effect of apolipoprotein E genotype
227. Determination in human cerebrospinal fluid of glial fibrillary acidic protein, S-100 and myelin basic protein as indices of non-specific or specific central nervous tissue pathology
228. Alzheimer disease: Protective factors
229. F4-isoprostanes as specific marker of docosahexaenoic acid peroxidation in Alzheimer's disease
230. Prospective measure of serum 3-nitrotyrosine levels in systemic lupus erythematosus: Correlation with disease activity
231. Laboratory examinations correlated with severity of dementia
232. Inducible nitric oxide synthase and nitrotyrosine are found in monocytes/macrophages and/or astrocytes in acute, but not in chronic, multiple sclerosis
233. Plasma 24S-hydroxycholesterol: A peripheral indicator of neuronal degeneration, and potential state marker for Alzheimer's disease
234. Ascorbate in healthy subjects, amyotrophic lateral sclerosis and Alzheimer's disease
235. Duration of expression of inducible nitric oxide synthase in glial cells
236. Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine, and o,o′-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson's disease
237. Association of antioxidants with memory in a multiethnic elderly sample using the Third National Health and Nutrition Examination Survey
238. Alpha 1-antichymotrypsin, and IL-1 beta are not increased in CSF or serum in Alzheimer's disease
239. Physical activity and oxidative stress during aging
240. F(2)-isoprostanes: Sensitive, and specific non-invasive indices of lipid peroxidation in vivo
241. Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: Correlation of a noninvasive index of lipid peroxidation with disease severity
242. Increased F2-isoprostanes in Alzheimer's disease: Evidence for enhanced lipid peroxidation in vivo
243. Nongenotoxic (epigenetic) carcinogens: Pesticides as an example. A critical review
244. Elevated plasma homocysteine levels in centenarians are not associated with cognitive impairment
245. Acute-phase protein synthesis in human hepatoma cells: Differential regulation of serum amyloid A (SAA) and haptoglobin by IL-1 and IL-6
246. Homocysteine and cardiovascular disease
247. Formation of novel D-ring and E-ring isoprostane-like compounds (D(4)/E(4)-neuroprostanes) in vivo from docosahexaenoic acid
248. Urinary isoprostane excretion is not confounded by the lipid content of the diet
249. Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive performance in the Normative Aging Study
250. Low plasma vitamin C in Alzheimer patients despite an adequate diet
251. Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid
252. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo
253. Clinical trial of indomethacin in Alzheimer's disease
254. CSF beta-amyloid, cognition, and APOE genotype in Alzheimer's disease
255. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study
256. Oxysterol regulators of 3-hydroxy-3-methylglutaryl-CoA reductase in liver. Effect of dietary cholesterol
257. Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies
258. Plasma levels of apolipoprotein E and genetic markers in elderly patients with Alzheimer's disease
259. Diagnostic criteria for vascular dementia
260. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
261. Apolipoprotein E serum concentration, and polymorphism in six european countries: The ApoEurope project
262. Plasma antioxidants and cognitive performance in middle-aged and older adults: Results of the Austrian Stroke Prevention Study
263. EUROCARE: A cross-national study of co-resident spouse carers for people with Alzheimer's disease: I - Factors associated with carer burden
264. B vitamins, homocysteine, and neurocognitive function in the elderly
265. Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease
266. Apolipoprotein E polymorphism, and serum concentration in Alzheimer's disease in nine European centres: The ApoEurope study. ApoEurope group
267. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons
268. Altered plasma antioxidant status in subjects with Alzheimer's disease and vascular dementia
269. Vascular factors and Alzheimer disease
270. Increased microglial activation and protein nitration in white matter of the aging monkey
271. Serum apolipoprotein E level is not increased in Alzheimer's disease: The Rotterdam study
272. Apolipoprotein E genotype, atherosclerosis, and cognitive decline: The Rotterdam Study
273. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease
274. Metabolic, metallic, and mitotic sources of oxidative stress in Alzheimer disease
275. Widespread peroxynitrite-mediated damage in Alzheimer's disease
276. Blood and cerebrospinal fluid anomalies in brain ageing and Alzheimer's disease
277. Sterol synthesis in vivo in 18 tissues of the squirrel monkey, guinea pig, rabbit, hamster, and rat
278. Apolipoprotein E genotypes, and cognitive functions in healthy elderly persons
279. Apolipoprotein E: High-avidity binding to beta-amyloid, and increased frequency of type 4 allele in late-onset familial Alzheimer disease
280. Neuronal DNA damage precedes tangle formation, and is associated with up-regulation of nitrotyrosine in Alzheimer's disease brain
281. Longitudinal stability of CSF tau levels in Alzheimer patients
282. Changes in the urinary excretion level of 8-hydroxyguanine by exposure to reactive oxygen-generating substances
283. Increased plasma apolipoprotein E (apoE) levels in Alzheimer's disease
284. Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease
285. Enzyme-linked immunosorbent assay for human autoantibody to glial fibrillary acidic protein: Higher titer of the antibody is detected in serum of patients with Alzheimer's disease
286. The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease
287. Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42, and 40 concentrations in Alzheimer's disease
288. Intracerebral production of TNF-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia
289. Nitrotyrosine in plasma of celiac disease patients as detected by a new sandwich ELISA
290. Increased levels of apolipoprotein D in cerebrospinal fluid and hippocampus of Alzheimer's patients
291. Autoantibodies in neurodegenerative diseases: Antigen-specific frequencies and intrathecal analysis
292. Developmental patterns of gene expression of secreted proteins in brain and choroid plexus
293. Concentrations of alpha-tocopherol and its quinone derivative in cerebrospinal fluid from patients with vascular dementia of the Binswanger type and Alzheimer type dementia
294. Alterations of 3-nitrotyrosine concentration in the cerebrospinal fluid during aging and in patients with Alzheimer's disease
295. Nitric oxide donors protect cultured rat astrocytes from 1-methyl-4-phenylpyridinium-induced toxicity
296. Assessment of homocysteine
297. Genetic control of human apolipoprotein E polymorphism: Comparison of one- and two-dimensional techniques of isoprotein analysis
298. [Model of costs of care for dementia: Community-dwelling vs. institutionalization]
299. Serum levels of IL-6 are not elevated in patients with Alzheimer's disease
300. Is the turbidimetric immunoassay of haptoglobin phenotype-dependent?
301. TGFbeta1, and TGFbeta2 concentrations are elevated in Parkinson's disease in ventricular cerebrospinal fluid
302. Haptoglobin types in Alzheimer's disease and senile dementia
303. Glial fibrillary acidic protein in the cerebrospinal fluid of patients with dementia
304. Fenton chemistry: An introduction
305. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors
306. Consensus Report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease." The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group
307. Oxygen-glucose deprivation induces inducible nitric oxide synthase and nitrotyrosine expression in cerebral endothelial cells
308. Decreased IL-6 level in the cerebrospinal fluid of patients with Alzheimer-type dementia
309. High expression of apolipoprotein E mRNA in the brains with sporadic Alzheimer's disease
310. Apolipoprotein E in cerebrospinal fluid: Relation to phenotype, and plasma apolipoprotein E concentrations
311. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2
312. Plasma concentrations of vitamins A and E and carotenoids in Alzheimer's disease
313. Genetic polymorphism in human apolipoprotein E
314. Superoxide-dependent cerebrovascular effects of homocysteine
315. Involvement of cytokines in normal CNS development and neurological diseases: Recent progress and perspectives